Kiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Quarterly Earnings Results

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11), Briefing.com reports. The firm had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The business’s revenue was up 65.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.18) earnings per share.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA traded up $0.20 during midday trading on Friday, hitting $17.81. 8,300 shares of the company traded hands, compared to its average volume of 399,241. The firm has a 50 day moving average of $19.32 and a 200-day moving average of $18.00. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of 160.11 and a beta of 0.27.

Analyst Ratings Changes

KNSA has been the topic of a number of analyst reports. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. Evercore ISI upped their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, TheStreet raised shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a report on Thursday, February 29th.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, CEO Sanj K. Patel sold 12,742 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Sanj K. Patel sold 12,742 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the sale, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 9,659 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at $377,262.60. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock valued at $709,929 in the last 90 days. Insiders own 54.23% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.